Inherited epidermolysis bullosa: recent basic and clinical advances.
OBJECTIVE
This review highlights key findings, both clinical and basic, that have been published in the field of inherited epidermolysis bullosa within the past few years.


RESULTS
New epidermolysis bullosa phenotypes, genotypes and modes of transmission have been identified, resulting in a revised classification system. Detailed evidence-based data are now available on the risk of extracutaneous complications in each of the major epidermolysis bullosa subtypes. Studies are now underway to try to better explain the biological aggressiveness of squamous cell carcinomas arising in epidermolysis bullosa skin. Cell and animal models have been refined and used to ascertain the feasibility of gene replacement therapy, stem cell transplantation, and treatment with injected allogeneic fibroblasts or recombinant type VII collagen. As a result, clinical trials are now being pursued to test each of these in humans.


CONCLUSIONS
Epidermolysis bullosa is caused by mutations in at least 14 genes, leading to a broad spectrum of entities, each of which has its own relative risk for the development of specific extracutaneous complications and/or premature death. Intensive research, both basic and clinical, is bringing us closer to more effective treatments and possibly even a cure.
Fine
Jo-David
JD
Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37204, USA. jo-david.fine@Vanderbilt.Edu
D004820:Epidermolysis Bullosa / Q000235:genetics* / Q000628:therapy; D020022:Genetic Predisposition to Disease; D005821:Genetic Techniques; D005838:Genotype; D006801:Humans; D011379:Prognosis; D012307:Risk Factors